Biopharma is starting to look healthier in 2026, but the recovery is not evenly distributed.
The headline numbers are encouraging. IQVIA reported that biopharma M&A reached about $130B in aggregate deal value in H1 2026, nearly matching the full-year 2025 total. BioPharma Dive also found that at least 68 venture-backed biotech companies raised more than $9.1B between January and June. Meanwhile, Fierce Biotech reported that layoff pressure eased in Q2, with 17 biopharma companies reporting cuts from April through June, down from 33 in Q1.
But for job seekers, the more important question is not “Is biotech back?” It is: where is the money going?
The answer seems clear: investors and acquirers are still being selective. Capital is flowing toward clinical-stage assets, clearer regulatory paths, and therapeutic areas with stronger commercial conviction. According to IQVIA, the top M&A therapy areas by value share in H1 2026 were oncology, immunology, neurology, women’s health, and rare diseases.
That matters for candidates because hiring usually follows business priorities. When capital moves toward later-stage assets, companies often need people who can help move programs through development, regulatory review, manufacturing readiness, and commercial preparation.
So instead of only tracking “hot biotech startups,” candidates should also track these hiring signals:
- Clinical-stage companies with recent funding, IPOs, or acquisition activityThese companies may need clinical operations, data management, regulatory, quality, and program management support.
- Oncology and immunology companiesThese areas continue to attract deal value and investor attention, which can translate into more active company pipelines and more specialized hiring.
- CMC, QA/QC, and manufacturing teamsWhen a drug program gets closer to clinical milestones or launch readiness, execution roles become more important. This is where CDMOs, manufacturing sites, validation teams, and quality groups can become strong job-search targets.
- Companies involved in M&A or licensing dealsM&A can create both opportunities and risk. Some teams expand after a deal; others consolidate. Candidates should watch pipeline updates, site strategy, integration news, and role postings after major transactions.
- Later-stage biotech, not just early discoveryEarly-stage innovation is still important, but the 2026 funding environment appears more cautious toward seed-stage and preclinical risk. For many candidates, the stronger near-term job opportunities may sit closer to clinical development and operations.
The takeaway: the market is not fully “back.” It is becoming more selective.
That means candidate strategy should be selective too. Follow the money, but do not stop at the headline deal value. Look at the therapeutic area, development stage, company pipeline, manufacturing needs, and whether the company is preparing for clinical, regulatory, or commercial milestones.
GetBioJob tracks biotech, pharma, and life science opportunities so candidates can build smarter company lists, not just send more applications.
Sources: IQVIA, BioPharma Dive, Fierce Biotech.